Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Caio Max S. Rocha Lima, Patrick J. Roberts, Victor M. Priego, Stephen G. Divers, Melanie B. Thomas, Ralph V. Boccia, Katie Stabler, Elizabeth Andrews, Rajesh K. Malik, Raid Aljumaily, John Turner Hamm, Vi Kien Chiu, Donald A. Richards, Petros Nikolinakos, Maen A. Hussein, Steven Robert Schuster, Robert John Hoyer, Geoffrey Shapiro, Konstantin H. Dragnev, Taofeek Kunle Owonikoko
Institutions: G1 Therapeutics (United States), Center for Cancers and Blood Disorders, Medical University of South Carolina, Pharmaceutical Product Development (United States), University of Oklahoma Medical Center, Norton Healthcare, UNM Comprehensive Cancer Center, Texas Oncology, University Cancer and Blood Center, Florida Cancer Specialists & Research Institute, University of Colorado System, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Dartmouth–Hitchcock Medical Center, Emory University
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2754274368